mRNA Skin Cancer Vaccine Phase 3: Interim Results, FDA Outlook, and Patient Impact

Quick Summary

• The Frontrunner: Moderna and Merck’s personalized mRNA vaccine (mRNA-4157/V940) combined with Keytruda is currently the most advanced skin cancer vaccine in Phase 3 trials (INTerpath-001).
• Latest Data (March 2026): Interim Phase 3 analyses corroborate earlier Phase 2b data, showing an approximately 49% reduction in the risk of recurrence or death for high-risk melanoma patients compared to Keytruda alone.
• FDA Status: Thanks to its Breakthrough Therapy Designation, an accelerated approval decision is anticipated by late 2026 or early 2027 based on robust metastasis-free survival endpoints.
• Manufacturing Breakthrough: The "vein-to-vein" time to sequence a patient's tumor and custom-print the vaccine has been successfully reduced to roughly 4-5 weeks.